Alectinib Approved for ALK-Positive Adjuvant NSCLC Alectinib Approved for ALK-Positive Adjuvant NSCLC

The approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news